The LanthaScreen™ Tb-Anti-LRRK2 [pSer935] Antibody enables researchers to interrogate phosphorylation at serine 935 of the Leucine-Rich Repeat Kinase-2 (LRRK2) protein in a cellular, high-throughput screening (HTS)-compatible, and TR-FRET format.

This antibody has been specifically developed and optimized for use in our LanthaScreen™ TR-FRET LRRK2 Cellular Activity Assay Kits (available for both wildtype and disease relevant mutant protein), which utilize the BacMam gene delivery system. The antibody, as well as other components of these assay kits, are also available separately. This assay format provides a convenient tool for the expression of LRRK2-GFP fusion protein in the cell background of your choice. The resulting cellular assay can be used to identify LRRK2 and relevant mutant inhibitor.

This product includes:

• LanthaScreen™ Tb-anti-LRRK2 [pSer935] Antibody, 1 mg (enough to perform 275 384-well plate assays)

Additional products needed for cell-based assay:

• BacMam LRRK2-GFP Wild Type Reagent, 15 mL or BacMam LRRK2-GFP G2019S Reagent, 15 mL
• LanthaScreen™ 6x Lysis Buffer, 50 mL
• Instrument Control Terbium TR-FRET Kit

Benefits of this assay include:

• More Physiologically Relevant: cell-based LRRK2 kinase activity and choice of cell background
• More Convenient: compatible with High Throughput Screening (HTS); LanthaScreen™ technology reduces interference and noise
• Disease Relevant: screen compound libraries for Parkinson's disease-relevant molecules

More Physiologically Relevant
The LanthaScreen™ Tb-Anti-LRRK2 [pSer935] Antibody allows the investigation of phosphorylation at serine 935 on LRRK2 protein kinase. When paired with LRRK2 BacMam reagents, you have the freedom to choose the cellular background for your assay, including primary cells. This enables screening for potential inhibitors of LRRK2 proteins in their natural complexes in a physiologically relevant cell type.

More Convenient
Assays are run in a fully homogenous, addition-only format without any of the washing, lysate transfer, or separation procedures required for traditional methods such as western blotting and ELISA, making this assay ideal for HTS applications. The LanthaScreen™ technology provides all of the advantages of TR-FRET ratiometric detection, including reduced data noise, less interference from fluorescent compounds, and high sensitivity, which results in the use of fewer cells than traditional Western or ELISA methods.

Disease Relevant
The LanthaScreen™ Tb-Anti-LRRK2 [pSer935] Antibody can be used by Parkinson's and other disease researchers to perform HTS, cell-based assays to generate inhibition curves (IC50) for their compound libraries. This will aid drug discovery efforts by reducing the time to results from 4 hrs to typically 1.5 hrs compared to alternative ELISAs.

For Research Use Only. Not intended for animal or human diagnostic or therapeutic use.

Related Links:
• LRRK2 tools for advancing Parkinson's disease research